← Back to patent-cliff list
PL-3301
Tier C — Watch / tradePL-3301
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Oral candidiasis, Candidiasis, Bacterial infection, Fungal infection, Skin and skin structure infection
Regional status
US
Phase I
2024-06-14
EU
-
China
Phase II
2026-08-19
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of PL-3301?
Approved indications include: Oral candidiasis, Candidiasis, Bacterial infection, Fungal infection, Skin and skin structure infection.
When does the PL-3301 patent expire?
No public expiry year is available for PL-3301 yet; this page updates once verified.
How do I get a quote for PL-3301 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29